Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Anixa’s oncology programs are using the body’s immune system to take multiple approaches in fighting cancer—developing treatments and vaccines. Anixa’s infectious disease program consists of a treatment for COVID-19 focused on inhibiting certain protein function necessary for viral replication.
Therapeutics
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
We are developing a treatment for COVID-19 that is designed to inhibit protein function necessary for replication of SARS-CoV-2, the virus causing the disease.
Vaccines
We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.
Latest News & Events
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
Read More...Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
Read More...Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
Read More...